阿莫西林二联方案根除幽门螺杆菌疗效与安全性的网状Meta分析
x

请在关注微信后,向客服人员索取文件

篇名: 阿莫西林二联方案根除幽门螺杆菌疗效与安全性的网状Meta分析
TITLE: Network meta-analysis of the efficacy and safety of dual amoxicillin-based regimens for Helicobacter pylori eradication
摘要: 目的 评价阿莫西林联用质子泵抑制剂(PPI)或钾离子竞争性酸阻滞剂(P-CAB)根除幽门螺杆菌(Hp)的有效性与安全性。方法检索PubMed、Embase、theCochraneLibrary、WebofScience、中国知网、万方数据、维普网,收集阿莫西林联合PPI或P-CAB根除Hp的随机对照试验(RCT),检索时限为建库起至2025年9月5日。筛选文献、提取资料、评价文献质量后,采用Stata17.0软件进行网状Meta分析。结果共纳入12项RCT,共计5515例患者,涉及8种干预措施,分别为PPI联合高剂量阿莫西林14d(TR1)、PPI联合低剂量阿莫西林14d(TR2)、P-CAB联合高剂量阿莫西林7d(TR3)、P-CAB联合高剂量阿莫西林14d(TR4)、P-CAB联合高剂量阿莫西林10d(TR5)、P-CAB联合低剂量阿莫西林7d(TR6)、P-CAB联合低剂量阿莫西林14d(TR7)和P-CAB联合低剂量阿莫西林10d(TR8)。网状Meta分析结果显示,在意向性治疗的Hp根除率方面,TR5和TR4的根除率显著高于TR3、TR8、TR6和TR1(P<0.05);累积排序概率曲线下面积(SUCRA)从高到低依次为:TR4(89.7%)>TR5(82.3%)>TR7(71.5%)>TR2(48.6%)>TR1(43.9%)>TR8(28.7%)>TR3(22.7%)>TR6(12.6%)。在安全性方面,TR3、TR5的不良反应发生率显著低于TR1(P<0.05);SUCRA从高到低依次为:TR1(91.3%)>TR4(79.8%)>TR5(55.0%)>TR7(50.9%)>TR8(41.3%)>TR2(36.4%)>TR3(27.6%)>TR6(17.7%)。结论尽管P-CAB联合高剂量阿莫西林14d的疗效最佳,但P-CAB联合高剂量阿莫西林10d在疗效与安全性方面表现更均衡。
ABSTRACT: OBJECTIVE To evaluate the efficacy and safety of amoxicillin combined with proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB) for Helicobacter pylori (Hp) eradication. METHODS Randomized controlled trial (RCTs) on amoxicillin combined with PPI or P-CAB for Hp eradication were retrieved from PubMed, Embase, the Cochrane Library, Web of Science, CNKI, Wanfang, and VIP data. The search time frame was from database inception to September 5, 2025. After literature screening, data extraction, and quality assessment, a network meta-analysis was performed using Stata 17.0 software. RESULTS A total of 12 RCTs involving 5 515 patients were included, encompassing 8 therapeutic regimens: PPI combined with high-dose amoxicillin for 14 days (TR1), PPI combined with low-dose amoxicillin for 14 days (TR2), P-CAB combined with high-dose amoxicillin for 7 days (TR3), P-CAB combined with high-dose amoxicillin for 14 days (TR4), P-CAB combined with high-dose amoxicillin for 10 days (TR5), P-CAB combined with low-dose amoxicillin for 7 days (TR6), P-CAB combined with low-dose amoxicillin for 14 days (TR7), and P-CAB combined with low-dose amoxicillin for 10 days (TR8). The network meta-analysis results showed that, in terms of intention-to-treat Hp eradication rates, the eradication rates of TR5 and TR4 were significantly higher than those of TR3, TR8, TR6 and TR1 ( P <0.05). The surface under the cumulative ranking curve (SUCRA) values from highest to lowest were: TR4 (89.7%)>TR5 (82.3%)>TR7 (71.5%)> TR2 (48.6%)>TR1 (43.9%)>TR8 (28.7%)>TR3 (22.7%)>TR6 (12.6%). Regarding safety, the incidence of adverse reactions in TR3 and TR5 was significantly lower than that in TR1 ( P <0.05). The SUCRA values from highest to lowest were: TR1 (91.3%)>TR4 (79.8%)>TR5 (55.0%)>TR7 (50.9%)>TR8 (41.3%)>TR2 (36.4%)>TR3 (27.6%) >TR6 (17.7%). CONCLUSIONS Although the regimen of P-CAB combined with high-dose amoxicillin for 14 days demonstrates the best efficacy, the combination of P-CAB with high-dose amoxicillin for 10 days exhibits a better balanced profile in terms of both efficacy and safety.
期刊: 2026年第37卷第08期
作者: 宋子文;原鑫淼;罗俐媛;何雨芳;杨玲淑;黄译续;佘建朋;魏培涵;郭思涵;段飞
AUTHORS: SONG Ziwen,YUAN Xinmiao, LUO Liyuan,HE Yufang,YANG Lingshu,HUANG Yixu,SHE Jianpeng,WEI Peihan,GUO Sihan,DUAN Fei
关键字: 阿莫西林;幽门螺杆菌;二联方案;质子泵抑制剂;钾离子竞争性酸阻滞剂;网状Meta分析;疗效;安全性
KEYWORDS: amoxicillin; Helicobacter pylori; dual therapy; proton pump inhibitor; potassium-competitive acid blocker;
阅读数: 5 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!